OSE Immunotherapeutics S.A.
OSE.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | -0.16 | -2.15 | 0.90 |
| FCF Yield | 30.93% | -23.88% | -15.04% | -5.57% |
| EV / EBITDA | 4.51 | -6.33 | -10.86 | -13.86 |
| Quality | ||||
| ROIC | 36.67% | -32.29% | -17.63% | -14.91% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.29 | 0.86 | 1.03 | 0.59 |
| Growth | ||||
| Revenue 3-Year CAGR | 56.30% | -56.09% | 20.66% | 0.45% |
| Free Cash Flow Growth | 341.86% | -7.93% | -78.29% | 47.41% |
| Safety | ||||
| Net Debt / EBITDA | 0.71 | -1.55 | -1.46 | -0.26 |
| Interest Coverage | 13.25 | -10.13 | -13.47 | -19.89 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 21.61 | 295.84 | 162.10 | 22.12 |